ArticleFrontiers in immunology2026
Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The COVID-19 pandemic, driven by the SARS-CoV-2 virus, has posed significant global health challenges, exacerbated by the emergence of the highly mutable Omicron variant. This study explores the potential of bispecific antibodies (bsAbs) in neutralizing this variant more effectively compared to traditional monoclonal antibodies (mAbs) and their combinations. Materials and methods: A comprehensive approach was utilized involving a fully human antibody phage-display library, Omni-Mab, to identify and enrich phage clones specific to SARS-CoV-2. Recombinant spike receptor-binding domain (RBD) proteins from the Omicron variant and other strains served as antigens during the biopanning process to ensure a broad screening. Post-enrichment, the binding affinity of the antibodies to the spike proteins of various strains was rigorously evaluated. Antibodies demonstrating strong binding efficacy were strategically combined and engineered into bsAbs. The neutralizing efficacy of these bsAbs was subsequently tested using various strains of the SARS-CoV-2 pseudo-viruses. Results: Selected parental mAbs showed kinetic profiles ranging from 5.71 x 10- Conclusion: The research unveiled two highly promising bsAbs, namely, R3-1a-1/R4-1a-10 scFv and R4-21/R4-1a-51 scFv. These bsAbs showed strong binding and neutralizing activity across the tested Omicron subvariants and retained activity against selected non-Omicron pseudovirus strains evaluated in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.